

**FDA Office of Generic Drugs Office of Research & Standards (ORS)**  
**Journal Articles Published by External Collaborators and ORS Staff in Fiscal Year 2015**

1. Azimi M, Longest P, Hindle M. Towards clinically relevant in vitro testing of locally acting nasal spray suspension products, *Respiratory Drug Delivery Europe*. 2015;1:121-130.
2. Babiskin AH, Zhang X. Application of Physiologically Based Absorption Modeling for Amphetamine Salts Drug Products in Generic Drug Evaluation, *J Pharm Sci*. 2015;104(9):3170-3182.
3. Chang RK, Raw A, Lionberger R, Yu L. Erratum to: Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products, *AAPS J*. 2015;17(6):1522.
4. Connarn JN, Zhang X, Babiskin A, Sun D. Metabolism of Bupropion by Carbonyl Reductases in Liver and Intestine, *Drug Metab Dispos*. 2015 Jul;43(7):1019-27. doi: 10.1124/dmd.115.063107.
5. Cshai E, Kangarlou S, Xiang TX, Ponta A, Bummer P, Choi D, Anderson BD. Development And Validation Of A Mechanism-Based Model For Doxorubicin Release From Actively Loaded Liposomes, *J Pharm Sci* 2015 Mar;104(3):1087-98.
6. Cshai E, Kangarlou S, Xiang TX, Ponta A, Bummer P, Choi D, Anderson BD. Determination Of Key Parameters For A Mechanism-Based Model To Predict Doxorubicin Release From Actively Loaded Liposomes, *J Pharm Sci* 2015 Mar;104(3):1087-98.
7. Depasquale R, Lee SL, Saluja B, Shur J, Price R. The Influence of Secondary Processing on the Structural Relaxation Dynamics of Fluticasone Propionate, *AAPS PharmSciTech*. 2015;16(3):589-599.
8. Fugit KD, Xiang TX, Choi DH, Kangarlou S, Cshai E, Bummer PM, Anderson BD. Mechanistic Model And Analysis Of Doxorubicin Release From Liposomal Formulations, *Journal of Controlled Release* 217 (2015) 82-91.
9. Garner J, Skidmore S, Park H, Park K, Choi S, Wang Y. A Protocol For Assay Of Poly(Lactide-Co-Glycolide) In Clinical Products, *Int J Pharm*. 2015 Nov 10;495(1):87-92.
10. Grosser S, Park M, Raney SG, Rantou E. Determining Equivalence for Generic Locally Acting Drug Products, *Statistics in Biopharmaceutical Research*. 2015;7(4):337-345.
11. Hens B, Corsetti M, Spiller R, Marciani L, Vanuytsel T, Tack J, Talattof A, Amidon GL, Koziol M, Weitschies W, Wilson CG, Bennisink RJ, Brouwers J, Augustijns P. Exploring Gastrointestinal Variables Affecting Drug And Formulation Behavior: Methodologies, Challenges And Opportunities, *Int J Pharm*. S0378-5173(16)31126-7. doi: 10.1016/j.ijpharm. 2016.11.063.
12. Holt J, Sandell D, Hickey A, Vallorz E, Straughn K. The Influence of Formulation Variables on the Performance of a Beclomethasone Dipropionate Metered Dose Inhaler, *Respiratory Drug Delivery (RDD) Europe Conference*. 2015;2:275-280.
13. Jiang W, Makhlof F, Schuirmann DJ, Zhang X, Zheng N, Conner D, Yu LX, Lionberger R. A bioequivalence approach for generic narrow therapeutic index drugs: evaluation of the reference-scaled approach and variability comparison criterion, *AAPS Journal*. 2015;17(4): 891-901.
14. Kesselheim AS, Gagne JJ. Product-Specific Regulatory Pathways To Approve Generic Drugs: The Need For Follow-Up Studies To Ensure Safety And Effectiveness, *Drug Saf*. 2015;38(10):849-53.

15. Kesselheim AS, Polinski JM, Fulchino LA, Isaman DL, Gagne JJ. Modified Regulatory Pathways To Approve Generic Drugs In The US and a Systematic Review Of Their Outcomes, *Drugs* 2015;75(6):633-50.
16. Khajeh-Hosseini-Dalasm N, Longest PW. Deposition of particles in the alveolar airways: Inhalation and breath-hold with pharmaceutical aerosols, *J Aerosol Sci.* 2015; 79: 15-30.
17. Krieg BJ, Taghavi SM, Amidon GL, Amidon GE. In Vivo Predictive Dissolution: Comparing the Effect of Bicarbonate and Phosphate Buffer on the Dissolution of Weak Acids and Weak Bases, *J Pharm Sci.* 2015 Sep;104(9):2894-904.
18. Lee SL, Saluja B, García-Arieta A, Santos GML, Li Y, Lu S, Hou S, Rebello J, Vaidya A, Gogtay J, Purandare S, Lyapustina S. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India, *AAPS J.* 2015;17(5):1285-1304.
19. Levy M, Boyne M, Rogstad S, Skanchy D, Jiang X, Vidavsky IG. Marketplace Analysis Of Conjugated Estrogens: Determining The Consistently Present Steroidal Content With LC-MS, *AAPS J.* 2015;17(6):1438-1445.
20. Lu D, Lee SL, Lionberger RA, Choi S, Adams W, Caramenico HN, Chowdhury BA, Conner DP, Katial R, Limb S, Peters JR, Yu L, Seymour S, Li BV. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences, *AAPS J.* 2015;17(3):546-557.
21. Matsui K, Tsume Y, Amidon GE, Amidon GL. In Vitro Dissolution of Fluconazole and Dipyrindamole in Gastrointestinal Simulator (GIS), Predicting In Vivo Dissolution and Drug-Drug Interaction Caused by Acid-Reducing Agents, *Mol Pharm.* 2015 Jul 6;12(7):2418-28. doi: 10.1021/acs.molpharmaceut.5b00135.
22. Peng DY, Lionberger RA, Viehmann A, Iyer K, Yu LX. Using Control Charts to Evaluate Pharmaceutical Manufacturing Process Variability, *Pharmaceutical Engineering.* 2015;35(3):59-74.
23. Raney SG, Franz TJ, Lehman PA, Lionberger R, Chen ML. Pharmacokinetics-Based Approaches For Bioequivalence Evaluation Of Topical Dermatological Drug Products, *Clinical Pharmacokinetics.* 2015;54(11):1095-1106.
24. Rogstad S, Pang E, Sommers C, Hu M, Jiang X, Keire DA, Boyne M. Modern Analytics For Synthetically Derived Complex Drug Substances: NMR, AFFF-MALS, and MS Tests For Glatiramer Acetate, *Anal Bioanal Chem.* 2015;407:8647-8659.
25. Rygg A, Hindle M, Longest PW. Absorption And Clearance Of Pharmaceutical Aerosols In The Human Nose: Effects Of Nasal Spray Suspension Particle Size And Properties, *Pharmaceutical Research* 2015, 33(4):909-921.
26. Rygg A, Longest PW. Absorption and Clearance of Pharmaceutical Aerosols in the Human Nose: Development of a CFD Model, *Journal of Aerosol Medicine and Pulmonary Drug Delivery* 2015, 29 (5): 416-431.
27. Shen J, Choi S, Qu W, Wang Y, Burgess DJ. In Vitro-In Vivo Correlation Of Parenteral Risperidone Polymeric Microspheres, *J Control Release.* 2015 Nov 28;218:2-12.
28. Shen J, Burgess DJ. In Vitro-In Vivo Correlation For Complex Non-Oral Drug Products: Where Do We Stand? *Journal of Controlled Release.* 2015, 219: 644-51.

29. Shokati T, Bodenberger N, Gadpaille H, Schniedewind B, Vinks AA, Jiang W, Alloway RR, Christians U. Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MSMS, *J Vis Exp*. 2015;105(e52424).
30. Shokati T, et al. Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS, *J Vis Exp*. 2015;-105.
31. Shur J, Saluja B, Lee S, Tibbatts J, Price R. Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Bowder Inhalers, *AAPS J*. 2015;17(5):1105-1116.
32. Tian G, Hindle M, Lee S, Longest PW. Validating CFD predictions of pharmaceutical aerosol deposition with in vivo data, *Pharm Res*. 2015;32(10):3170-3187.
33. Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE. Generic Lamotrigine Versus Brand-Name Lamictal Bioequivalence in Patients with Epilepsy: A Field Test of the FDA Bioequivalence Standard, *Epilepsia*, 56(9):1415–1424, 2015 doi: 10.1111/epi.13095.
34. Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, Krumholz A, Temple R, Polli JE. Generic Substitution of AEDs: Is it Time to Put This Issue to Rest? *Epilepsia* 2015;56(9):1415–1424. doi:10.1111/epi.13095.
35. Trasi NS, Taylor LS. Dissolution Performance Of Binary Amorphous Drug Combinations—Impact Of A Second Drug On The Maximum Achievable Supersaturation, *Journal of Pharmaceutical Sciences* 2015; 496: 282-290.
36. Tsume Y, Takeuchi S, Matsui K, Amidon GE, Amidon GL. In Vitro Dissolution Methodology, Mini-Gastrointestinal Simulator (MGIS), Predicts Better In Vivo Dissolution of a Weak Base Drug, *Dasatinib*, *Eur J Pharm Sci*. 2015 Aug 30;76:203-12.
37. Vaithianathan S, et al. Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets, *Mol Pharmaceutics*. 2015;12: 2436–2443.
38. Vaithianathan S, Raman S, Jiang W, Ting TY, Kane MA, Polli JE. Biopharmaceutic Risk Assessment of Brand and Generic Lamotrigine Tablets, *Mol Pharmaceutics*. 2015;12(7):2436-2443.
39. Wang Y, Abrahamsson B, Lindfors L, Brasseur JG. Analysis Of Diffusion-Controlled Dissolution From Polydisperse Collections Of Drug Particles With An Assessed Mathematical Model, *J Pharm Sci*. 2015 Sep;104(9):2998-3017.
40. Wei X, Bormann K, Byron PR. Predicting Variations In Aerodynamic Particle Size Distribution Of The Lung Dose From Budelin® Novolizer®, *RDD Europe* 2015, 2: 533-536.
41. Wen H, Jung H, Li X. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges, *AAPS J*. 2015;17(6):1327-1340.
42. Yellepeddi VK, Palakurthi S. Recent Advances In Topical Ocular Drug Delivery, *J Ocular Pharmacol. Ther*.
43. Yu LX, Jiang W, Zhang X, Lionberger R, Makhlof F, Schuirmann DJ, Muldowney L, Chen M-L, Davit B, Conner D, Woodcock J. Novel bioequivalence approach for narrow therapeutic index drugs, *Clin Pharmacol Ther*. 2015;97(3):286-91.
44. Yu LX, Peng DY, Lionberger RA, Viehmann A, Iyer K. Using Process Capability to Ensure Pharmaceutical Quality, *Pharmaceutical Engineering*. 2015;35(2):34-43.
45. Zeng K, Vidavisky IG, Gucinski A, Jiang X, Boynell M. Liquid Chromatography-High Resolution Mass Spectrometry For Peptide Drug Quality Control, *AAPS J*. 2015;17(3):643-51.